Estradiol/medroxyprogesterone acetate

Estradiol /
medroxyprogesterone acetate
	Estradiol (top) and medroxy-; progesterone acetate (bottom)
Combination of
Estradiol	Estrogen
Medroxyprogesterone acetate	Progestogen
Clinical data
Trade names	Indivina, Tridestra
Other names	E2/MPA
Routes of; administration	By mouth
Drug class	Estrogen; Progestogen
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	215930-42-0;
PubChem CID	66978539;

Estradiol/medroxyprogesterone acetate (E2/MPA), sold under the brand names Indivina and Tridestra among others, is a combination product of estradiol, an estrogen, and medroxyprogesterone acetate, a progestogen, which is used in menopausal hormone therapy for the treatment of menopausal symptoms.^[1] It is taken by mouth.

v
t
e
Results of the Women's Health Initiative (WHI) menopausal hormone therapy randomized controlled trials
Clinical outcome	Hypothesized effect on risk	Estrogen and progestogen (CEsTooltip conjugated estrogens 0.625 mg/day p.o. + MPATooltip medroxyprogesterone acetate 2.5 mg/day p.o.) (n = 16,608, with uterus, 5.2–5.6 years follow up)			Estrogen alone (CEsTooltip Conjugated estrogens 0.625 mg/day p.o.) (n = 10,739, no uterus, 6.8–7.1 years follow up)
Clinical outcome	Hypothesized effect on risk	HRTooltip Hazard ratio	95% CITooltip Confidence interval	ARTooltip Attributable risk	HRTooltip Hazard ratio	95% CITooltip Confidence interval	ARTooltip Attributable risk
Coronary heart disease	Decreased	1.24	1.00–1.54	+6 / 10,000 PYs	0.95	0.79–1.15	−3 / 10,000 PYs
Stroke	Decreased	1.31	1.02–1.68	+8 / 10,000 PYs	1.37	1.09–1.73	+12 / 10,000 PYs
Pulmonary embolism	Increased	2.13	1.45–3.11	+10 / 10,000 PYs	1.37	0.90–2.07	+4 / 10,000 PYs
Venous thromboembolism	Increased	2.06	1.57–2.70	+18 / 10,000 PYs	1.32	0.99–1.75	+8 / 10,000 PYs
Breast cancer	Increased	1.24	1.02–1.50	+8 / 10,000 PYs	0.80	0.62–1.04	−6 / 10,000 PYs
Colorectal cancer	Decreased	0.56	0.38–0.81	−7 / 10,000 PYs	1.08	0.75–1.55	+1 / 10,000 PYs
Endometrial cancer	–	0.81	0.48–1.36	−1 / 10,000 PYs	–	–	–
Hip fractures	Decreased	0.67	0.47–0.96	−5 / 10,000 PYs	0.65	0.45–0.94	−7 / 10,000 PYs
Total fractures	Decreased	0.76	0.69–0.83	−47 / 10,000 PYs	0.71	0.64–0.80	−53 / 10,000 PYs
Total mortality	Decreased	0.98	0.82–1.18	−1 / 10,000 PYs	1.04	0.91–1.12	+3 / 10,000 PYs
Global index	–	1.15	1.03–1.28	+19 / 10,000 PYs	1.01	1.09–1.12	+2 / 10,000 PYs
Diabetes	–	0.79	0.67–0.93		0.88	0.77–1.01
Gallbladder disease	Increased	1.59	1.28–1.97		1.67	1.35–2.06
Stress incontinence	–	1.87	1.61–2.18		2.15	1.77–2.82
Urge incontinence	–	1.15	0.99–1.34		1.32	1.10–1.58
Peripheral artery disease	–	0.89	0.63–1.25		1.32	0.99–1.77
Probable dementia	Decreased	2.05	1.21–3.48		1.49	0.83–2.66
Abbreviations: CEs = conjugated estrogens. MPA = medroxyprogesterone acetate. p.o. = per oral. HR = hazard ratio. AR = attributable risk. PYs = person–years. CI = confidence interval. Notes: Sample sizes (n) include placebo recipients, which were about half of patients. "Global index" is defined for each woman as the time to earliest diagnosis for coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogen plus progestogen group only), hip fractures, and death from other causes. Sources: See template.

Notes and references[edit]

^ Clunie G, Keen RW (2014). Osteoporosis. Oxford University Press. pp. 74–. ISBN 978-0-19-871334-0.

This article about a steroid is a stub. You can help Wikipedia by expanding it.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[ClunieKeen2014-1] Clunie G, Keen RW (2014). Osteoporosis. Oxford University Press. pp. 74–. ISBN 978-0-19-871334-0.

[1]

See also[edit]

Notes and references[edit]